Literature DB >> 31512600

Survival model analysis of tuberculosis treatment among patients with human immunodeficiency virus coinfection.

Adeboye Azeez1, Ruffin Mutambayi1, Akinwumi Odeyemi1, James Ndege1.   

Abstract

Background: Tuberculosis (TB) with human immunodeficiency virus (HIV) coinfection is the highest clinical epidemiology and public health issue. Despite many programs established to tackle the epidemic, TB target controls have not been reached. One of the many factors attributed to the failure in TB treatment is HIV coinfection. The aim of this study is to assess the survival rate of HIV infection among TB patients and the risk factors of death among the TB patients with HIV coinfection during the retro of directly observed treatment, short-course (DOTS) program.
Methods: This study is a retrospective cohort conducted to compare the survivorship between TB/HIV patients for 8 months DOTS. Death among TB patients was considered as failures and those defaulted or survived were censored. The Cox proportional-hazards regression and log-linear model were used to establish the hazard ratio (HR) of death for each variable at baseline and estimate the risk factors effect among TB patients.
Results: The findings revealed that 50% of death from TB/HIV patients were from HIV coinfection (advanced HR = 2.01, 95% confidence interval = 1.13-3.17). The risk of death was significantly higher in HIV-positive TB patients (P = 0.000) during the extension care phase. TB/HIV-positive patients on antiretroviral therapy have decreased survival rate (log-rank test = 14.88, df = 2, P = 0.0001). The probability of TB patients surviving is significantly decreased in HIV positive with some factors such as age, weight, smoking, and alcohol found significant.
Conclusion: The probability of survival in HIV-positive TB patients was significantly lower during the TB treatment. Weight loss, age, alcohol, smoking, and pregnancy were showed to affect the survival probability of TB/HIV patients' coinfection significantly.

Entities:  

Keywords:  Bactrim; drug-resistant; hazard ratio; treatment outcomes; tuberculosis/human immunodeficiency virus coinfection

Mesh:

Substances:

Year:  2019        PMID: 31512600     DOI: 10.4103/ijmy.ijmy_101_19

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  4 in total

1.  Survival Analysis and Associated Factors for Pulmonary Tuberculosis Death: Evidence from the Information System of Tuberculosis Disease and Mortality Surveillance in China.

Authors:  Kui Liu; Liyun Ai; Jin Pan; Fangrong Fei; Songhua Chen; Yu Zhang; Wei Wang; Qian Wu; Bin Chen; Junhang Pan; Jieming Zhong
Journal:  Risk Manag Healthc Policy       Date:  2022-05-31

2.  A systematic review of the quality of conduct and reporting of survival analyses of tuberculosis outcomes in Africa.

Authors:  Moses M Ngari; Susanne Schmitz; Christopher Maronga; Lazarus K Mramba; Michel Vaillant
Journal:  BMC Med Res Methodol       Date:  2021-04-27       Impact factor: 4.615

3.  Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in South Africa.

Authors:  Goedele Louwagie; Mona Kanaan; Neo Keitumetse Morojele; Andre Van Zyl; Andrew Stephen Moriarty; Jinshuo Li; Kamran Siddiqi; Astrid Turner; Noreen Dadirai Mdege; Olufemi Babatunde Omole; John Tumbo; Max Bachmann; Steve Parrott; Olalekan A Ayo-Yusuf
Journal:  BMJ Open       Date:  2022-02-14       Impact factor: 2.692

4.  Mortality and associated factors among adult patients on tuberculosis treatment in Tanzania: A retrospective cohort study.

Authors:  Elias M Bukundi; Francis Mhimbira; Rogath Kishimba; Zuweina Kondo; Candida Moshiro
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.